OrbiMed Secures $3 Billion for New Global and Asia Focused Healthcare Funds
On October 15, 2026, OrbiMed, a prominent player in the healthcare investment landscape, announced a substantial fundraising achievement. The firm has successfully secured $3 billion in commitments for two innovative private equity funds, namely OrbiMed Private Investments X and OrbiMed Asia Partners VI. This funding signifies a robust commitment to investing in life sciences, particularly in U.S., European, and Asian markets.
Investment Details
OrbiMed Private Investments X aims to channel over $1.9 billion into various life sciences venture capital initiatives in the U.S. and Europe. Meanwhile, OrbiMed Asia Partners VI has successfully attracted over $1 billion dedicated to healthcare growth equity and venture capital projects throughout Asia. Both funds will strategically focus on building and nurturing leading healthcare enterprises that target sectors like biopharmaceuticals, medical devices, diagnostics, and technology-enabled health services.
Carl Gordon, a managing partner at OrbiMed, expressed enthusiasm for the timing of these investments, stating, "There has never been a more exciting time to invest in life sciences innovation. The integration of AI, a surge in new therapeutic strategies, and China’s ascendancy as a biotechnology leader are broadening our horizons for developing transformative treatments. We anticipate assisting entrepreneurs in leveraging these advancements to establish top-tier healthcare firms."
Local and Global Reach
OrbiMed operates from a network of 12 global offices positioned strategically across key healthcare markets, enabling them to harness a vast pool of expertise. With a managing team of 20 partners and an extensive support staff of over 150 professionals, the company demonstrates a multifaceted approach, combining incubation, strategy formulation, operational excellence, and financial insight to maximize investment impact.
The backing for these funds showcases a diverse group of investors, including notable medical institutions, university endowments, philanthropic foundations, pension funds, sovereign wealth entities, and family offices, which reinforces the trust and confidence in OrbiMed’s strategic vision.
Carter Neild, another managing partner at OrbiMed, conveyed appreciation for the unwavering support from the firm’s extensive network of long-term investors and assured that they would diligently strive to meet and potentially surpass the high expectations set before them.
OrbiMed's Overall Vision
With over $21 billion in assets under management, OrbiMed is dedicated to fostering innovation across the healthcare spectrum, from emerging startups to established multinational companies. Their investment strategies span private equity funds, public equity engagement, and royalty-related credit investments. OrbiMed positions itself as the preferred capital provider, offering tailored financial solutions backed by an extensive global network, aiming to cultivate world-class healthcare companies.
To learn more about OrbiMed and its initiatives, please visit www.orbimed.com.
Investment Details
OrbiMed Private Investments X aims to channel over $1.9 billion into various life sciences venture capital initiatives in the U.S. and Europe. Meanwhile, OrbiMed Asia Partners VI has successfully attracted over $1 billion dedicated to healthcare growth equity and venture capital projects throughout Asia. Both funds will strategically focus on building and nurturing leading healthcare enterprises that target sectors like biopharmaceuticals, medical devices, diagnostics, and technology-enabled health services.
Carl Gordon, a managing partner at OrbiMed, expressed enthusiasm for the timing of these investments, stating, "There has never been a more exciting time to invest in life sciences innovation. The integration of AI, a surge in new therapeutic strategies, and China’s ascendancy as a biotechnology leader are broadening our horizons for developing transformative treatments. We anticipate assisting entrepreneurs in leveraging these advancements to establish top-tier healthcare firms."
Local and Global Reach
OrbiMed operates from a network of 12 global offices positioned strategically across key healthcare markets, enabling them to harness a vast pool of expertise. With a managing team of 20 partners and an extensive support staff of over 150 professionals, the company demonstrates a multifaceted approach, combining incubation, strategy formulation, operational excellence, and financial insight to maximize investment impact.
The backing for these funds showcases a diverse group of investors, including notable medical institutions, university endowments, philanthropic foundations, pension funds, sovereign wealth entities, and family offices, which reinforces the trust and confidence in OrbiMed’s strategic vision.
Carter Neild, another managing partner at OrbiMed, conveyed appreciation for the unwavering support from the firm’s extensive network of long-term investors and assured that they would diligently strive to meet and potentially surpass the high expectations set before them.
OrbiMed's Overall Vision
With over $21 billion in assets under management, OrbiMed is dedicated to fostering innovation across the healthcare spectrum, from emerging startups to established multinational companies. Their investment strategies span private equity funds, public equity engagement, and royalty-related credit investments. OrbiMed positions itself as the preferred capital provider, offering tailored financial solutions backed by an extensive global network, aiming to cultivate world-class healthcare companies.
To learn more about OrbiMed and its initiatives, please visit www.orbimed.com.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.